Table 4.
Comparison of screening strategies across the SCOOP, ROSE and SOS studies in women
| Age range | SCOOP | ROSE | SOS |
|---|---|---|---|
| 70–85 years | 65–80 years | 65–90 years | |
| Number recruited (with baseline FRAX if different) |
Control 6250 Screening 6233 |
Control 17,157 (9326) Screening 17,072 (9279) |
Control 5457 Screening 5575 |
| 1st screening step | |||
| Assessment | FRAX 10-year hip probability without BMD | FRAX 10-year MOF probability without BMD | FRAX 10-year MOF probability with BMD (plus VFA) |
| Definition of positive test | Probability ≥ age-dependent assessment threshold | Probability ≥ 15% or more | See treatment criteria below |
| 2nd screening step | |||
| Assessment | DXA measurement of BMD | DXA measurement of BMD | N/A |
| Treatment criteria | Probability (with BMD) ≥ age-dependent intervention threshold | BMD T-score ≤ − 2.5 | Probability ≥ age-dependent thresholds + BMD T score ≤ − 2, or a prevalent vertebral fracture, or met criteria within Dutch guidelines |
| Performance per prevented fracture | |||
| NNS/NNT (Ost fracture) NNS/NNT (Hip fracture) |
133/19 115/17 |
319/34 281/30 |
178/32 552/98 |